Clinical Trials

Liverpool Researchers Report Novltex, a Synthetic Antibiotic Class Against Multidrug-Resistant Bacteria

A peer-reviewed paper details a modular, lipid II–targeting design that shows strong in‑vitro activity, with animal studies next.